Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin

D. J. Greenblatt, D. R. Abernethy, H. G. Boxenbaum, R. Matlis, H. R. Ochs, J. S. Harmatz, R. I. Shader

Research output: Contribution to journalArticle

Abstract

Salicylate kinetics following single, 640-mg intravenous and oral doses of aspirin were evaluated in humans in 2 studies. Complete conversion of aspirin to salicylate was assumed. The first study involved 25 young (25-40 years) and 21 elderly (66-89 years) healthy male and female volunteers. Mean salicylate clearance was lower in elderly females compared with that in young females; however, the difference between young men and elderly men was not significant. Salicylate free fraction in plasma increased significantly with age in men and women. After correction for free fraction, unbound mean clearance was reduced in elderly men compared with young men, and in elderly women compared with young women. Peak plasma salicylate concentrations after taking oral aspirin were not significantly influenced by age, and systemic availability of salicylate in all groups was complete. The second study compared 20 obese subjects (mean weight 113 kg) with 20 normal weight controls (mean weight 67 kg) matched for age, sex, height, and smoking habits. Small differences between obese and control groups were observed in total salicylate volume of distribution (V(d)), unbound V(d), and mean clearance of total or unbound salicylate. Following normalization for total weight, however, values of total V(d) and mean clearance were significantly smaller in obese subjects than in normal weight subjects. Rate and completeness of salicylate absorption were not influenced by obesity when aspirin was ingested, although peak levels were lower in obese subjects. If applied to multiple doses, the reduced unbound clearance of salicylate in the elderly would imply increased accumulation unless doses are appropriately adjusted downward. During long-term therapy, salicylate dosage for obese individuals should not be adjusted upward in proportion to total weight.

Original languageEnglish (US)
Pages (from-to)971-980
Number of pages10
JournalArthritis and Rheumatism
Volume29
Issue number8
StatePublished - 1986
Externally publishedYes

Fingerprint

Salicylates
Aspirin
Obesity
Weights and Measures
Habits
Volunteers
Smoking

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Greenblatt, D. J., Abernethy, D. R., Boxenbaum, H. G., Matlis, R., Ochs, H. R., Harmatz, J. S., & Shader, R. I. (1986). Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. Arthritis and Rheumatism, 29(8), 971-980.

Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. / Greenblatt, D. J.; Abernethy, D. R.; Boxenbaum, H. G.; Matlis, R.; Ochs, H. R.; Harmatz, J. S.; Shader, R. I.

In: Arthritis and Rheumatism, Vol. 29, No. 8, 1986, p. 971-980.

Research output: Contribution to journalArticle

Greenblatt, DJ, Abernethy, DR, Boxenbaum, HG, Matlis, R, Ochs, HR, Harmatz, JS & Shader, RI 1986, 'Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin', Arthritis and Rheumatism, vol. 29, no. 8, pp. 971-980.
Greenblatt DJ, Abernethy DR, Boxenbaum HG, Matlis R, Ochs HR, Harmatz JS et al. Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. Arthritis and Rheumatism. 1986;29(8):971-980.
Greenblatt, D. J. ; Abernethy, D. R. ; Boxenbaum, H. G. ; Matlis, R. ; Ochs, H. R. ; Harmatz, J. S. ; Shader, R. I. / Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. In: Arthritis and Rheumatism. 1986 ; Vol. 29, No. 8. pp. 971-980.
@article{b67e61bfbe2f4889bc018e5a8f919d3f,
title = "Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin",
abstract = "Salicylate kinetics following single, 640-mg intravenous and oral doses of aspirin were evaluated in humans in 2 studies. Complete conversion of aspirin to salicylate was assumed. The first study involved 25 young (25-40 years) and 21 elderly (66-89 years) healthy male and female volunteers. Mean salicylate clearance was lower in elderly females compared with that in young females; however, the difference between young men and elderly men was not significant. Salicylate free fraction in plasma increased significantly with age in men and women. After correction for free fraction, unbound mean clearance was reduced in elderly men compared with young men, and in elderly women compared with young women. Peak plasma salicylate concentrations after taking oral aspirin were not significantly influenced by age, and systemic availability of salicylate in all groups was complete. The second study compared 20 obese subjects (mean weight 113 kg) with 20 normal weight controls (mean weight 67 kg) matched for age, sex, height, and smoking habits. Small differences between obese and control groups were observed in total salicylate volume of distribution (V(d)), unbound V(d), and mean clearance of total or unbound salicylate. Following normalization for total weight, however, values of total V(d) and mean clearance were significantly smaller in obese subjects than in normal weight subjects. Rate and completeness of salicylate absorption were not influenced by obesity when aspirin was ingested, although peak levels were lower in obese subjects. If applied to multiple doses, the reduced unbound clearance of salicylate in the elderly would imply increased accumulation unless doses are appropriately adjusted downward. During long-term therapy, salicylate dosage for obese individuals should not be adjusted upward in proportion to total weight.",
author = "Greenblatt, {D. J.} and Abernethy, {D. R.} and Boxenbaum, {H. G.} and R. Matlis and Ochs, {H. R.} and Harmatz, {J. S.} and Shader, {R. I.}",
year = "1986",
language = "English (US)",
volume = "29",
pages = "971--980",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin

AU - Greenblatt, D. J.

AU - Abernethy, D. R.

AU - Boxenbaum, H. G.

AU - Matlis, R.

AU - Ochs, H. R.

AU - Harmatz, J. S.

AU - Shader, R. I.

PY - 1986

Y1 - 1986

N2 - Salicylate kinetics following single, 640-mg intravenous and oral doses of aspirin were evaluated in humans in 2 studies. Complete conversion of aspirin to salicylate was assumed. The first study involved 25 young (25-40 years) and 21 elderly (66-89 years) healthy male and female volunteers. Mean salicylate clearance was lower in elderly females compared with that in young females; however, the difference between young men and elderly men was not significant. Salicylate free fraction in plasma increased significantly with age in men and women. After correction for free fraction, unbound mean clearance was reduced in elderly men compared with young men, and in elderly women compared with young women. Peak plasma salicylate concentrations after taking oral aspirin were not significantly influenced by age, and systemic availability of salicylate in all groups was complete. The second study compared 20 obese subjects (mean weight 113 kg) with 20 normal weight controls (mean weight 67 kg) matched for age, sex, height, and smoking habits. Small differences between obese and control groups were observed in total salicylate volume of distribution (V(d)), unbound V(d), and mean clearance of total or unbound salicylate. Following normalization for total weight, however, values of total V(d) and mean clearance were significantly smaller in obese subjects than in normal weight subjects. Rate and completeness of salicylate absorption were not influenced by obesity when aspirin was ingested, although peak levels were lower in obese subjects. If applied to multiple doses, the reduced unbound clearance of salicylate in the elderly would imply increased accumulation unless doses are appropriately adjusted downward. During long-term therapy, salicylate dosage for obese individuals should not be adjusted upward in proportion to total weight.

AB - Salicylate kinetics following single, 640-mg intravenous and oral doses of aspirin were evaluated in humans in 2 studies. Complete conversion of aspirin to salicylate was assumed. The first study involved 25 young (25-40 years) and 21 elderly (66-89 years) healthy male and female volunteers. Mean salicylate clearance was lower in elderly females compared with that in young females; however, the difference between young men and elderly men was not significant. Salicylate free fraction in plasma increased significantly with age in men and women. After correction for free fraction, unbound mean clearance was reduced in elderly men compared with young men, and in elderly women compared with young women. Peak plasma salicylate concentrations after taking oral aspirin were not significantly influenced by age, and systemic availability of salicylate in all groups was complete. The second study compared 20 obese subjects (mean weight 113 kg) with 20 normal weight controls (mean weight 67 kg) matched for age, sex, height, and smoking habits. Small differences between obese and control groups were observed in total salicylate volume of distribution (V(d)), unbound V(d), and mean clearance of total or unbound salicylate. Following normalization for total weight, however, values of total V(d) and mean clearance were significantly smaller in obese subjects than in normal weight subjects. Rate and completeness of salicylate absorption were not influenced by obesity when aspirin was ingested, although peak levels were lower in obese subjects. If applied to multiple doses, the reduced unbound clearance of salicylate in the elderly would imply increased accumulation unless doses are appropriately adjusted downward. During long-term therapy, salicylate dosage for obese individuals should not be adjusted upward in proportion to total weight.

UR - http://www.scopus.com/inward/record.url?scp=0022498267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022498267&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 971

EP - 980

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 8

ER -